Multiple sclerosis is an autoimmune disease that affects the central nervous system.
多发性硬化是一种影响中枢神经系统的自身免疫性疾病。
The patient was diagnosed with primary progressive multiple sclerosis five years ago.
这位患者在五年前被诊断为原发性进行性多发性硬化。
Sclerosis of the arteries can lead to increased risk of heart attack and stroke.
动脉硬化会增加心脏病发作和中风的风险。
In the later stages of the disease, sclerosis may cause significant physical disabilities.
在疾病的后期，硬化可能导致显著的身体残疾。
The doctor recommended lifestyle changes to slow down the progression of atherosclerosis.
医生建议改变生活方式以减缓动脉粥样硬化的进程。
Research into new treatments for multiple sclerosis offers hope for patients worldwide.
针对多发性硬化的新疗法研究给全球患者带来了希望。
Corticosteroids are sometimes used to manage the symptoms of acute exacerbations in multiple sclerosis.
皮质类固醇有时用于管理多发性硬化急性加重期的症状。
A healthy diet and regular exercise can help prevent the development of sclerosis.
健康饮食和规律运动有助于预防硬化的发生。
The process of sclerosis involves the thickening and stiffening of tissues or organs.
硬化过程涉及组织或器官的增厚和硬化。
Early detection and treatment of sclerosis-related conditions can significantly improve outcomes.
早期发现和治疗与硬化相关的疾病可以显著改善预后。
BEIJING — A group of Chinese researchers has created a gene target therapy drug for amyotrophic lateral sclerosis, or ALS.
北京——一组中国研究人员开发了一种针对肌萎缩侧索硬化症（ALS）的基因靶向治疗药物。
In the past several decades, it has developed many breakthrough therapies, including Lantus (insulin glargine), Taxotere (anti-cancer drug), Lovenox (anti-coagulant), Aubagio (multiple sclerosis), and Cerezyme (Gaucher disease).
在过去的几十年里，它开发了许多突破性疗法，包括Lantus（甘精胰岛素）、Taxotere（抗癌药物）、Lovenox（抗凝血药）、Aubagio（多发性硬化症）和Cerezyme（Gaucher病）。
According to Reed, Sanofi has prioritized multiple potentially transformative therapies in areas of high unmet patient need, including Dupixent, the world's first targeted biological agent that has been approved for treating moderate-to-severe atopic dermatitis, Fitusiran and Efanesoctocog alfa (BIVV001) for treatment of hemophilia, Amlitelimab for treatment of inflammatory disorders, Amcenestrant for treatment of breast cancer, RSV Vaccine Nirsevimab, and Tolebrutinib for treatment of multiple sclerosis.
据Reed介绍，赛诺菲已将多种潜在的变革性疗法优先用于患者需求未得到高度满足的领域，包括世界上第一种被批准用于治疗中重度特应性皮炎的靶向生物制剂Dupixent，用于治疗血友病的Fitusiran和Efanesoctocog alfa（BIVV001），用于治疗炎症性疾病的Amlitelimab，Amcenestant治疗乳腺癌症，RSV疫苗Nirsevimab和Tolebrutinib治疗多发性硬化症。
US-based Biogen Inc and Hong Kong-listed Chinese mainland biopharma startup InnoCare Pharma Ltd announced on Monday that they have entered into a license and collaboration agreement for orelabrutinib, a drug candidate currently in a multi-country, placebo-controlled Phase 2 trial for the potential treatment of multiple sclerosis, a rare disease of the nervous system characterized by loss of feeling and control of movement and speech.
美国生物技术公司Biogen Inc和在香港上市的中国内地生物制药初创公司InnoCare Pharma Ltd于周一宣布，双方已就orelabrutinib达成许可和合作协议。Orelabrutinib是一种药物候选物，目前正在进行跨国、安慰剂对照的二期临床试验，用于治疗多发性硬化症(MS)这一罕见的神经系统疾病，该疾病以感觉丧失、运动和言语控制能力下降为特征。
The firm's performance in its healthcare division was driven by immuno-oncology therapy Bavencio and multiple sclerosis therapy Mavenclad, which together helped the unit to produce organic sales growth of 5.2 percent last year.
Aubagio, the first new oral drug for the treatment of multiple sclerosis, a rare disease of the nervous system characterized by loss of feeling and control of movement and speech, has been launched in China just prior to the expo, taking only 58 days from approval to launch and setting a record thanks to Chinese authorities' accelerated approval for new drug listings and launches, the company said.
Founded in Darmstadt, Germany in 1668, we have become truly global – with more than 50,000 employees in 66 countries working on breakthrough solutions and vibrant technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.
InnoCare Pharma Ltd, also founded in 2015, announced in mid-July a license and collaboration agreement with US-based Biogen Inc－a recognized leader in neuroscience－for orelabrutinib, a drug candidate for the potential treatment of multiple sclerosis.
成立于2015年的InnoCare Pharma Ltd于7月中旬宣布，已与美国知名神经科学领域领导者Biogen Inc达成一项关于orelabrutinib的授权与合作协议。该药物候选产品有望用于多发性硬化症的治疗。
"The approach is critical to solving major brain diseases like Amyotrophic Lateral Sclerosis, and has shown good performance in the level and safety of device implantation," said Tao Hu, vice-dean of the institute.
未经许可，严禁转发。QQ交流群：688169419